Linking Ubiquitin Research to Drug Discovery

Home » News & Events » News

Rapid Identification of Redox Cycling Compounds – REDOXprofiler™

Posted on August 22nd, 2018 in News
Dundee, UK – 22nd August 2018: Ubiquigent Limited, a company specialising in providing ubiquitin cell-signalling system drug discovery services, research tools and novel targeted chemistry, announced today that it has launched REDOXprofiler™.  The new service, validated following a collaboration with… Read More »

Ubiquigent awarded Innovate UK grant, closes further round of investment and strengthens management team

Posted on August 15th, 2018 in News
Dundee, UK, 15th August 2018: Ubiquigent Limited, a company focused on enabling and supporting ubiquitin system targeted drug discovery, announced today that it was awarded a new grant from Innovate UK as part of its Investor Accelerator Pilot to support… Read More »

Ubiquigent and Forma Therapeutics enter an exclusive R&D collaboration to develop novel DUB inhibitors

Posted on April 5th, 2018 in News
Dundee, UK, 5th April 2018: Ubiquigent Limited announced today that it has entered into a multi-year strategic R&D collaboration agreement with FORMA Therapeutics for the design and development of novel deubiquitylase (DUB) enzyme inhibitors.  Under the terms of the collaboration… Read More »

Use of Ubiquigent’s DUBprofiler™ services in key 2017 publications

Posted on January 16th, 2018 in News

Ubiquigent awarded Innovate UK grant

Posted on January 19th, 2017 in News
Ubiquigent awarded Innovate UK grant to develop novel compound libraries targeting deubiquitylase (DUB) enzymes Dundee, UK, 19th January 2017: Ubiquigent Limited, a company specialising in providing ubiquitin cell-signalling system drug discovery services and research tools, announced today that it has… Read More »

Ubiquigent launches first novel compound library

Posted on September 14th, 2016 in News
Ubiquigent launches the first novel compound library designed to target Deubiquitylase (DUB) enzymes - DUBtarget™-001 Dundee, UK, 14th September, 2016: Ubiquigent Limited, a company specialising in providing ubiquitin cell-signalling system drug discovery services and research tools, announced today that it… Read More »

Horizon & Ubiquigent Enter into Collaboration Agreement

Posted on May 26th, 2016 in News
Horizon's X-MAN® cell lines to be made available in conjunction with Ubiquigent's ubiquitin-related Drug Discovery Services   Cambridge, UK, 26 May 2016: Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies including… Read More »

Dundee, UK – the place to access world class ubiquitin system research expertise and capabilities

Posted on May 12th, 2016 in News
Take a look at a great article that was published today in Nature describing how the Division of Signal Transduction Therapy (DSTT) enables pre-competitive access to ubiquitin system research at the University of Dundee. Our friends at the University of… Read More »

Ubiquigent Strengthens Team to Deliver Cutting Edge Drug Discovery Services, Research Tools and Chemistry and Announces Launch of New Website

Posted on February 24th, 2016 in News
Dundee, UK, 24th February, 2016: Ubiquigent Limited, a company specialising in providing ubiquitin cell-signalling system drug discovery services and research tools, announced today that it has significantly enhanced its drug discovery service capabilities by strengthening its commercial and chemistry teams… Read More »

Ubiquigent and Cyclofluidic Enter into Collaboration to Build Novel Ubiquitin System Targeted Compound Libraries

Posted on June 3rd, 2015 in News
Agreement combines ubiquitin focused biology expertise with proprietary chemistry platform to identify small molecule libraries that target the ubiquitin system. Dundee, UK, 3rd June 2015: Ubiquigent Limited, a company specialising in ubiquitin cell-signalling system drug discovery capabilities and services, and… Read More »